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Milan and 4) Department of Health Sciences, University of Milano – Bicocca, Respiratory Unit, AO San Gerardo, Monza, ItalyAbstractThere is no evidence supporting the use of de-escalation therapy (DET) among patients with community-acquired pneumonia (CAP).We assessed
theoutcomes associatedwithDET among bacteraemicCAPpatients.Weperformed a secondary analysis of theCommunity-Acquired Pneumonia
Organization database, which contains data on 660 bacteraemic patients hospitalized because of CAP in 35 countries (2001–2013). Exclusion
criteria were death within 72 h from admission and an inappropriate empirical antibiotic regimen. DET was deﬁned as changing an appropriate
empirical broad-spectrum regimen to a narrower-spectrum regimen according to culture results within 7 days from hospital admission. Two
study groups were identiﬁed: patients whose antibiotic therapy was de-escalated (the DET group), and patients whose antibiotic therapy was
not de-escalated (the N-DET group). The primary study outcome was 30-day mortality. Two hundred and sixty-one bacteraemic CAP
patients were included. Gram-positive bacteria were responsible for 88.1% of the cases (Streptococcus pneumoniae, 75.9%). Gram-negative
bacteria were responsible for for 7.3% of the cases. DET was performed in 165 patients (63.2%). The N-DET group was characterized by a
more severe presentation at admission. After adjustment for confounders, DET was not associated with an increased risk of 30-day mortality.
DET seems to be safe among bacteraemic patients with CAP. Randomized clinical trials are warranted to further explore these ﬁndings.
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E-mail: carugatimanuela@gmail.comIntroductionPneumonia is a predominant cause of sepsis, severe sepsis, and
septic shock [1]. Mortality rates among patients with
community-acquired pneumonia (CAP) range from 1% to
17.5% [2]. Empirical broad-spectrum antimicrobial treatment
is aimed at achieving adequate antimicrobial coverage, and
thus reducing mortality [3]. However, there is a risk thatMicrobiol Infect 2015; 21: 936.e11–936.e18
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.015empirical broad-spectrum antimicrobial treatment can expose
patients to overuse of antimicrobials and increase the resis-
tance of microorganisms to treatment [4]. De-escalation has
been proposed as a strategy to replace initial empirical broad-
spectrum antimicrobial treatment with narrower-spectrum
antimicrobial therapy [5]. This is done by either changing
the pharmacological agent or discontinuing a pharmacological
combination according to the patient’s microbial culture
results.
To date, there is conﬂicting evidence as to whether de-
escalation of antimicrobial agents is effective and safe for
adults with sepsis, severe sepsis, and septic shock [6–12].
Therefore, it is not possible to either recommend or not
recommend the de-escalation of antimicrobial agents in clinical
practice for bacteraemic patients with CAP [13].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Carugati et al. De-escalation in bacteraemic patients with pneumonia 936.e12The aim of this study was to evaluate de-escalation therapy
(DET) and its impact on clinical outcomes in bacteraemic pa-
tients hospitalized with CAP.Materials and methodsStudy design
Secondary analysis was restricted to bacteraemic patients
included in the Community-Acquired Pneumonia Organization
(CAPO) database. The CAPO database contains retrospective
data on 660 bacteraemic adult patients with CAP hospitalized
during the period 2001–2013 in 35 countries. The study pro-
tocol and data collection form are available at the study website
(www.caposite.com). This study was conducted in accordance
with the amended Declaration of Helsinki. The local institu-
tional review board approved the protocol (University of
Louisville Human Subjects Protection Program, IRB approval
number 11.0613) [14].
Study population
Patients included in the study were aged 18 years and were
characterized by the identiﬁcation of bacteria likely to be the
causative agents of pneumonia on blood cultures performed at
hospital admission. Exclusion criteria included the following: (a)
a single blood culture yielding coagulase-negative staphylococci,
Bacillus species, Corynebacterium species, Propionibacterium spe-
cies, andMicrococcus species [15]; (b) an inappropriate empirical
broad-spectrum antibiotic regimen; and (c) death within 72 h
from hospital admission, before de-escalation could have been
instituted.
Study deﬁnitions
CAP was deﬁned as a new pulmonary inﬁltrate (within 24 h from
admission), associated with at least one of the following factors: a
new or increased cough, an abnormal temperature (<35.8°C or
>37.8°C), or an abnormal leukocyte count [16]. Pneumonia was
considered as community-acquired if a patient had no history of
hospitalization during the 2 weeks prior to admission. Severe
sepsis was deﬁned as the presence of at least one of the following
signs of organ hypoperfusion or organ dysfunction on admission:
(a) sepsis-induced hypotension, (b) a lactate level of >2 mmol/L,
(c) urine output of <0.5 mL/kg/h for >2 h, (d) a creatinine level of
>2.0 mg/dL, (e) a bilirubin level of >2mg/dL, (f) a platelet count of
<100 000 cells/L, or (g) coagulopathy (international normalized
ratio of >1.5) [17]. DET was deﬁned as changing an initially
appropriate antimicrobial therapy from an empirical broad-
spectrum regimen to a narrower-spectrum regimen (either by
changing the antimicrobial agent or by discontinuing an eventual
antimicrobial combination, or both) according to the microbialClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeculture results within 7 days from hospital admission [18–20].
The empirical broad-spectrum antibiotic regimen was based on
internationally approved guidelines for CAP (American Thoracic
Society and the European Respiratory Society guidelines), and
the following regimens were considered to be initial empirical
broad-spectrum antibiotic regimens: (a) a β-lactam plus a mac-
rolide, (b) a β-lactam plus a ﬂuoroquinolone, (c) a ﬂuo-
roquinolone plus aztreonam, (d) an aminopenicillin/β-lactamase
inhibitor or antipseudomonal β-lactam, (e) an antipseudomonal
β-lactam plus a ﬂuoroquinolone, (f) an antipseudomonal β-lac-
tam plus an aminoglycoside and a macrolide, (g) vancomycin or
linezolid added to regimen (e) or (f), and (h) a β-lactam plus
clindamycin or metronidazole [21,22]. An empirical broad-
spectrum antibiotic regimen was considered to be appropriate
when it was characterized by in vitro-demonstrated or presumed
(for Mycoplasma pneumoniae, Chlamydia pneumoniae, and
Legionella pneumophila) activity against the causative microor-
ganism. Multidrug resistance: among Gram-positive bacteria,
methicillin-resistant Staphylococcus aureus was considered to be
multidrug resistant, and the following Gram-negative pathogens
were considered to be multidrug resistant: (a) Enterobacteriaceae
producing extended-spectrum β-lactamase or carbapenemases;
(b) Pseudomonas aeruginosa resistant to antipseudomonal peni-
cillins, cephalosporins, carbapenems, and quinolones; (c) Steno-
trophomonas maltophilia; and (d) Acinetobacter baumanii resistant
to cephalosporins, carbapenems, and aminoglycoside [23,24].
Time to clinical stability (TCS) was deﬁned according to the
American Thoracic Society 2001 criteria for switching therapy
from intravenous to oral antibiotic therapy [25]. Speciﬁcally, TCS
was calculated as the number of days from the date of admission
to the date when the patient met clinical stability criteria. Clinical
stability was deﬁned as follows: improved clinical signs (improved
cough and shortness of breath), lack of fever for8 h, improving
leukocytosis (decreased by 10% from the previous day), and
tolerating oral intake. The criteria for clinical stability were
evaluated daily during hospitalization.
Study groups and outcomes
Among the entire study population, two groups of patients
were identiﬁed according to the presence of DET: patients
whose antibiotic therapy was de-escalated (DET group), and
patients whose antibiotic therapy was not de-escalated (N-DET
group).
Clinical failure during hospitalization, 30-day mortality and
length of stay (LOS) in the hospital were the study outcomes.
Clinical failure was deﬁned by the occurrence of one of the
following events: (a) acute pulmonary deterioration with the
need for mechanical ventilation, (b) acute haemodynamic dete-
rioration, or (c) in-hospital death up to 28 days after hospital
admission [26]. Thirty-day mortality was deﬁned as death fromctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 936.e11–936.e18
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FIG. 1. Study population.
936.e13 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIany cause within 30 days from hospital admission. LOS was
calculated among patients alive at discharge as the number of
days from the date of admission to the date of discharge.
Study objectives
The primary objective of the study was to compare the 30-day
mortality rate among patients whose antibiotic therapy was de-
escalated (DET group) and patients whose antibiotic therapy
was not de-escalated (N-DET group). Secondary objectives of
the study included the following: (a) to compare clinical failure
rates (DET group vs. N-DET group), (b) to compare 30-day
mortality rates and clinical failure rates in the setting of se-
vere sepsis (DET group vs. N-DET group), and (c) to compare
30-day mortality rates and clinical failure rates in the setting of
monomicrobial Streptococcus pneumoniae infections (DET group
vs. N-DET group).
Statistical analysis
Clinical outcomes were compared between the two study
groups. A subgroup analysis in patients with severe sepsis and in
those with monomicrobial S. pneumoniae infections was also
performed. Continuous variables are presented as medians
with interquartile ranges (IQRs). Categorical variables are
presented as frequencies and percentages of the speciﬁed
group. Comparisons between groups were performed with the
Fisher exact test or the Kruskal–Wallis test as appropriate.
As DET may simply be a marker of early clinical improve-
ment and not be causally associated with the outcomes under
study, multivariable modelling was conducted to adjust for
confounding effects in the relationships between DET and 30-
day mortality, and between DET and clinical failure. To eval-
uate the adjusted association between DET and the outcomes
(30-day mortality and clinical failure), a Poisson regression
model was used. This model was chosen to calculate the
adjusted risk ratio (RR) between the predictor and outcome.
Poisson models are traditionally used for outcomes consisting
of count data, and often suffer from issues associated with
overdispersion. To correct for this and appropriately use this
model in the situation of a binary outcome, we used a modiﬁed
Poisson regression model with robust error variance [27]. In
this model, we adjusted for the following variables: Pneumonia
Severity Index, empirical antimicrobial therapy including a
macrolide, need for intensive-care unit (ICU) admission or
transfer, and severe sepsis. Model ﬁt was evaluated with the
Hosmer–Lemeshow goodness-of-ﬁt test. p-Values of 0.05
were considered to be statistically signiﬁcant in all analyses. For
analysis, we used SAS enterprise guide v5.1 (SAS Institute, Cary,
NC, USA) and R v3.1.2 (R Foundation for Statistical Computing,
Vienna, Austria). The following R packages were used: sandwich
[28] and rms [29].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectResultsStudy population
Complete microbiological therapeutic and outcome data were
available for 414 of the 660 bacteraemic patients included in
CAPO database. Of these, the following were excluded from
our analysis: bacteraemia due to pathogens not consistent with
CAP (single blood culture positive for coagulase-negative
staphylococci, n = 13), inappropriate initial empirical broad-
spectrum antibiotic regimen (n = 78), and death within 72 h
from hospital admission (n = 34). Among those patients whose
therapy was de-escalated, 28 were excluded from the study
because DET occurred after 8 days from hospital admission.
Thus, there were 261 evaluable subjects (Fig. 1): 96 in the N-
DET group (36.8%), and 165 in the DET group (63.2%).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 936.e11–936.e18
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The median time from initiation of empirical antibiotic therapy
to de-escalation was 3.0 days (IQR 3.0–5.0 days), and the
median time from clinical stability to de-escalation was −1.0
days (IQR −4.0 to 1.0 days). Baseline demographics and
comorbidities of the study population are summarized in
Table 1, according to the two study groups. Despite a similar
distribution of Pneumonia Severity Index Risk Classes IV–V, the
clinical presentation at admission was more severe among pa-
tients in the N-DET group. This was shown by TCS. The me-
dian TCS in the study population was 6.0 days (IQR 3.0–8.0
days), with a signiﬁcant difference between the N-DET group
and the DET group (8.0 days (IQR 4.0–8.0 days) vs. 5.0 days
(IQR 3.0–8.0 days), respectively, p < 0.01). The median dura-
tion of antibiotic therapy in the study population was 12 daysTABLE 1. Baseline demographics, comorbidities, disease severity,
antibiotic data, and outcome information of the study population, a
Demographic data
Age (years), median (IQR)
Male sex, n (%)
Comorbidities, n (%)
Neoplastic disease
Chronic heart failure
Cerebrovascular disease
Renal disease
Liver disease
Neurological disease
Diabetes mellitus
Chronic obstructive pulmonary disease
HIV infection
Nursing home resident
Severity indicators
Admission to ICU at hospital arrival, n (%)
Transfer to ICU during hospital stay, n (%)
PSI class IV–V, n (%)
Heart rate (beats/min), median (IQR)
Respiratory rate (breaths/min), median (IQR)
White blood cell count, cell × 103/mm3, median (IQR)
Systolic blood pressure (mmHg), median (IQR)
Severe sepsis, n (%)
Microbiology, n (%)
Gram-positive infections
Gram-negative infections
Mixed infections
Multidrug-resistant pathogen
Management and clinical progression, median (IQR)
Time from arrival to antibiotic therapy (h)
Time from diagnosis to antibiotic therapy (h)
Time from sample collection to DET (days)
Time from TCS to DET (days)
TCS (days)
Duration of antibiotic therapy (days)
Initial empirical broad-spectrum antibiotic regimen, n (%)
β-Lactam plus a macrolide
β-Lactam plus a ﬂuoroquinolone
β-Lactam plus clindamycin or metronidazole
Aminopenicillin/β-lactamase inhibitor or antipseudomonal β-lactam
Antipseudomonal β-lactam plus a ﬂuoroquinolone
Antipseudomonal β-lactam plus an aminoglycoside and macrolide
Antipseudomonal β-lactam plus an aminoglycoside + macrolide or a ﬂuoroquinolone
plus vancomycin or linezolid
Clinical outcomes
Length of hospital stay among patients alive at discharge (days), median (IQR)
Clinical failure, n (%)
30-day mortality, n (%)
Statistically signiﬁcant p-values are in bold.
DET, de-escalation therapy; HIV, human immunodeﬁciency virus; ICU, intensive-care unit; IQ
clinical stability.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infe(IQR 8–15 days). The duration of treatment was longer among
patients in the DET group (13 days (IQR 9–16 days) vs. 10.5
days (IQR 7–14 days), respectively, p < 0.01] (Table 1). The
vast majority of the infections were due to Gram-positive
bacteria in both groups (86.1% and 91.7% in the DET group
and the N-DET group, respectively). Overall, Gram-negative
infections and mixed infections accounted for 7.3% and 4.6%
of the cases, respectively. S. pneumoniae was the most
frequently isolated pathogen (75.9%). Non-fermenters (Pseu-
domonas species, n = 3; Moraxella catarrhalis, n = 4; Acinetobacter
baumanii, n = 1; Stenotrophomonas maltophilia, n = 1) and
Enterobacteriaceae (Escherichia coli, n = 4; Klebsiella species,
n = 4; Citrobacter species, n = 1; Enterobacter species, n = 1;
Proteus species, n = 1) were the leading pathogens among
Gram-negative bacteria. Multidrug-resistant organisms wereclinical, and laboratory ﬁndings on admission, microbiology,
ccording to the two study groups
N-DET group
(n [ 96) DET group (n [ 165) p
59.5 (44.0–77.5) 54.0 (40.0–71.0) 0.03
62/96 (64.6) 94/165 (56.9) 0.22
11/96 (11.5) 15/165 (9.1) 0.54
10/96 (10.4) 21/165 (12.7) 0.58
10/96 (10.4) 12/165 (7.3) 0.38
12/96 (12.5) 14/165 (8.5) 0.30
8/96 (8.3) 20/165 (12.1) 0.34
14/96 (14.6) 8/165 (4.9) <0.01
18/96 (18.8) 32/165 (19.4) 0.89
12/96 (12.5) 22/165 (13.3) 0.85
8/96 (8.3) 30/165 (18.2) 0.03
7/47 (14.9) 11/88 (12.5) 0.70
31/96 (32.3) 36/165 (21.8) 0.06
5/70 (7.1) 13/124 (10.5) 0.44
59/96 (61.5) 89/165 (53.9) 0.24
107.5 (94.0–120.0) 110.0 (99.0–125.0) 0.18
26.5 (20.0–32.0) 24.0 (20.0–28.0) 0.19
13.0 (9.9–21.0) 15.0 (9.0–19.6) 0.89
108.5 (93.5–130.0) 116.0 (101.5–134.5) 0.07
49/96 (51.0) 65/165 (39.4) 0.07
88/96 (91.7) 142/165 (86.1) 0.18
4/96 (4.2) 15/165 (9.1) 0.14
4/96 (4.2) 8/165 (4.8) 1.00
5/96 (5.2) 11/165 (6.7) 0.63
3.5 (2.0–6.2) 4.0 (2.0–6.0) 0.56
1.0 (0.0–3.0) 1.0 (0.0–2.5) 0.94
NA 3.0 (3.0–5.0) NA
NA –1.0 (–4.0 to 1.0) NA
8.0 (4.0–8.0) 5.0 (3.0–8.0) <0.01
10.5 (7.0–14.0) 13.0 (9.0–16.0) <0.01
44/96 (45.8) 86/165 (52.1) 0.33
25/96 (26.0) 27/165 (16.4) 0.06
2/96 (2.1) 6/165 (3.6) 0.71
6/96 (6.25) 4/165 (2.4) 0.18
7/96 (7.3) 7/165 (4.2) 0.29
0/96 (0.0) 1/165 (0.6) 1.00
12/96 (12.5) 34/165 (20.6) 0.09
9.0 (5.0–16.0) 8.0 (5.0–15.0) 0.64
27/66 (40.9) 28/104 (26.9) 0.06
24/96 (25.0) 25/165 (15.1) 0.04
R, interquartile range; NA, not applicable; PSI, Pneumonia Severity Index; TCS, time to
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 936.e11–936.e18
TABLE 3. Thirty-day mortality: multivariate analysis
Risk ratio 95% CI p
Model intercept 0.05 0.02–0.12 <0.01
De-escalation 0.78 0.47–1.27 0.32
Pneumonia Severity Index class IV–V 1.01 1.01–1.02 <0.01
Macrolide therapy 1.18 0.71–1.95 0.53
Need for intensive care 2.07 1.17–3.68 0.01
Severe sepsis 1.02 0.59–1.75 0.94
Statistically signiﬁcant p-values are in bold.
936.e15 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIisolated in 6.1% of the cases (MRSA, n = 15; Stenotrophomonas
maltophilia, n = 1) (Table 1). A β-lactam plus either a macrolide
or a ﬂuoroquinolone was the empirical treatment most
frequently administered to patients in both the DET group and
the N-DET group (Table 1).
30-day mortality
Among the entire study population, a total of 49 patients
(18.8%) died within 30 days from hospital admission (Table 2).
The characteristics of patients who died vs. those who survived
are reported in Table 2. There was a signiﬁcantly lower 30-day
mortality rate in the DET group than in the N-DET group in
univariate analysis (25 patients (15.1%) vs. 24 patients (25.0%), p
0.04) (Tables 1 and 2). After adjustment for confounders, DET
was not associated with an increased risk of 30-day mortality
(RR 0.78 (95% CI 0.47–1.27), p 0.32) (Table 3).
Clinical failure
To assess the performance of DET, we analysed several other
outcome metrics. Data on clinical failure were available for 170TABLE 2. Thirty-day mortality: univariate analysis
Demographic data
Age (years), median (IQR)
Male sex, n (%)
Comorbidities, n (%)
Neoplastic disease
Chronic heart failure
Cerebrovascular disease
Renal disease
Liver disease
Neurological disease
Diabetes mellitus
Chronic obstructive pulmonary disease
HIV infection
Nursing home resident
Severity indicators
Admission to ICU at hospital arrival, n (%)
Transfer to ICU during hospital stay, n (%)
PSI score IV–V, n (%)
Heart rate (beats/min), median (IQR)
Respiratory rate (breaths/min), median (IQR)
White blood cell count, cell × 103/mm3, median (IQR)
Systolic blood pressure (mmHg), median (IQR)
Severe sepsis, n (%)
Microbiology, n (%)
Gram-positive infections
Gram-negative infections
Polymicrobial infections
Multidrug-resistant pathogen
Management and clinical progression, median (IQR)
Time from arrival to antibiotic therapy (h)
Time from diagnosis to antibiotic therapy (h)
Time from sample collection to DET (days)
Time from TCS to DET (days)
TCS (days)
Initial empirical broad-spectrum antibiotic regimen, n (%)
β-Lactam plus a macrolide
β-Lactam plus a ﬂuoroquinolone
β-Lactam plus clindamycin or metronidazole
Aminopenicillin/β-lactamase inhibitor or antipseudomonal β-lactam
Antipseudomonal β-lactam plus a ﬂuoroquinolone
Antipseudomonal β-lactam plus an aminoglycoside and macrolide
Antipseudomonal β-lactam plus an aminoglycoside + macrolide or a ﬂuoroquinolone plus
vancomycin or linezolid
DET, n (%)
Statistically signiﬁcant p-values are in bold.
DET, de-escalation therapy; HIV, human immunodeﬁciency virus; IQR, interquartile range; P
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectpatients. Among these patients, 55 (32.3%) experienced a
clinical failure. A lower rate of clinical failure was detected in
the DET group than in the N-DET group (28 patients (26.9%)
vs. 27 patients (40.9%), p 0.06) (Tables 1 and 4). Similarly to
what was found for the 30-day-mortality risk, the risk of clinical
failure was not increased among those patients whose antibiotic
therapy was de-escalated (RR 0.89 (95% CI 0.63–1.27), p 0.54)
(Table 5). The median LOS among patients alive at discharge
was 8 days (IQR 5–16 days). No difference in terms of LOS wasAlive at day 30 (n [ 212) Died by day 30 (n [ 49) p
54.5 (40.5–71.0) 58.0 (45.0–80.0) 0.06
126/212 (59.4) 30/49 (61.2) 0.82
21/212 (9.9) 5/49 (10.2) 1.00
21/212 (9.9) 10/49 (20.4) 0.04
10/212 (4.7) 12/49 (24.5) <0.01
22/212 (10.4) 4/49 (8.2) 0.79
22/212 (10.4) 6/49 (12.2) 0.70
13/212 (6.1) 9/49 (18.4) 0.01
40/212 (18.9) 10/49 (20.4) 0.80
24/212 (11.3) 10/49 (20.4) 0.09
30/212 (14.2) 8/49 (16.3) 0.70
10/102 (9.8) 8/33 (24.2) 0.04
44/212 (20.8) 23/49 (46.9) <0.01
14/168 (8.3) 4/26 (15.4) 0.27
109/212 (51.4) 39/49 (79.6) <0.01
110.0 (95.5–122.0) 114.0 (99.0–128.0) 0.34
24.0 (20.0–30.0) 30.0 (20.0–40.0) 0.03
15.0 (9.9–22.7) 12.0 (4.0–15.0) <0.01
115.0 (100.0–133.0) 101.5 (85.5–122.0) 0.05
86/212 (40.6) 28/49 (57.1) 0.03
188/212 (88.7) 42/49 (85.7) 0.56
13/212 (6.1) 6/49 (12.2) 0.14
11/212 (5.2) 1/49 (2.0) 0.47
11/212 (5.2) 5/49 (10.2) 0.19
4.0 (2.0–6.0) 3.5 (2.0–7.0) 0.82
1.0 (0.0–2.5) 1.0 (0.0–3.0) 0.74
3.0 (3.0–5.0) 3.0 (2.0–5.0) 0.76
−1.0 (−4.0 to 1.0) −3.0 (−5.0 to 2.0) <0.01
5.0 (2.0–8.0) 8.0 (8.0–8.0) <0.01
109/212 (51.4) 21/49 (42.8) 0.28
45/212 (21.2) 7/49 (14.3) 0.27
7/212 (3.3) 1/49 (2.0) 1.00
9/212 (4.3) 1/49 (2.0) 0.69
8/212 (3.8) 6/49 (12.2) 0.03
1/212 (0.5) 0/49 (0.0) 1.00
33/212 (15.6) 13/49 (26.5) 0.07
140/212 (66.0) 25/49 (51.0) 0.04
SI, Pneumonia Severity Index; TCS, time to clinical stability.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 936.e11–936.e18
TABLE 4. Clinical failure: univariate analysis
Clinical success (n [ 115) Clinical failure (n [ 55) p
Demographic data
Age (years), median (IQR) 56.0 (44.0–75.0) 55.0 (40.0–79.0) 0.89
Male sex, n (%) 65/115 (56.5) 29/55 (52.7) 0.64
Comorbidities, n (%)
Neoplastic disease 13/115 (11.3) 3/55 (5.5) 0.22
Chronic heart failure 8/115 (6.9) 9/55 (16.3) 0.06
Cerebrovascular disease 6/115 (5.2) 12/55 (21.89 <0.01
Renal disease 13/115 (11.39 7/55 (12.7) 0.79
Liver disease 8/115 (6.9) 7/55 (12.7) 0.25
Neurological disease 8/115 (6.9) 12/55 (21.8) <0.01
Diabetes mellitus 26/115 (22.6) 9/55 (16.4) 0.35
Chronic obstructive pulmonary disease 14/115 (12.2) 10/55 (18.2) 0.29
HIV infection 21/115 (18.3) 13/55 (23.6) 0.41
Nursing home resident 6/18 (33.3) 8/28 (28.6) 0.73
Severity indicators
Admission to ICU at hospital arrival, n (%) 12/115 (10.4) 28/55 (50.9) <0.01
Transfer to ICU during hospital stay, n (%) 3/115 (2.6) 11/45 (24.4) <0.01
PSI score IV–V, n (%) 56/115 (48.7) 42/55 (76.4) <0.01
Heart rate (beats/min), median (IQR) 110.0 (94.0–121.0) 112.5 (100.0–125.0) 0.13
Respiratory rate (breaths/min), median (IQR) 24.0 (20.0–30.0) 27.5 (21.0–35.5) 0.01
White blood cell count, cell × 103/mm3, median (IQR) 15.1 (9.8–22.7) 12.6 (6.0–16.7) 0.04
Systolic blood pressure (mmHg), median (IQR) 116.0 (101.0–135.0) 105.0 (87.0–120.0) <0.01
Severe sepsis, n (%) 53/115 (46.1) 44/55 (80.0) <0.01
Microbiology, n (%)
Gram-positive infections 107/115 (93.0) 46/55 (83.6) 0.06
Gram-negative infections 4/115 (3.5) 7/55 (12.7) 0.02
Polymicrobial infections 4/115 (3.5) 2/55 (3.6) 1.00
Multidrug-resistant pathogen 6/115 (5.2) 7/55 (12.7) 0.12
Management and clinical progression, median (IQR)
Time from arrival to antibiotic therapy (h) 4.0 (2.0–6.0) 3.0 (1.5–6.0) 0.50
Time from diagnosis to antibiotic therapy (h) 1.0 (0.0–2.0) 0.5 (–0.5 to 2.5) 0.81
Time from sample collection to DET (days) 3.0 (3.0–5.0) 3.0 (2.0–4.5) 0.52
Time from TCS to DET (days) –1.0 (–3.5 to 1.0) –4.0 (–6.0 to 2.0) <0.01
TCS (days) 4.0 (2.0–8.0) 8.0 (8.0–8.0) <0.01
Initial empirical broad-spectrum antibiotic regimen, n (%)
β-Lactam plus a macrolide 58/115 (50.4) 19/55 (34.5) 0.05
β-Lactam plus a ﬂuoroquinolone 33/115 (28.7) 9/55 (16.4) 0.08
β-Lactam plus clindamycin or metronidazole 3/115 (2.6) 0/55 (0.0) 0.55
Aminopenicillin/β-lactamase inhibitor or antipseudomonal β-lactam 2/115 (1.7) 2/55 (3.6) 0.60
Antipseudomonal β-lactam plus a ﬂuoroquinolone 1/115 (0.8) 5/55 (9.1) 0.01
Antipseudomonal β-lactam plus an aminoglycoside and macrolide 0/115 (0.0) 0/55 (0.0) —
Antipseudomonal β-lactam plus an aminoglycoside + macrolide or a ﬂuoroquinolone plus
vancomycin or linezolid
18/115 (15.6) 20/55 (36.4) <0.01
DET, n (%) 76/115 (66.1) 28/55 (50.9) 0.06
Statistically signiﬁcant p-values are in bold.
DET, de-escalation therapy; HIV, human immunodeﬁciency virus; ICU, intensive-care unit; IQR, interquartile range; PSI, Pneumonia Severity Index; TCS, time to clinical stability.
CMI Carugati et al. De-escalation in bacteraemic patients with pneumonia 936.e16detected between the DET group and the N-DET group (8 days
(IQR 5–13.5 days) vs. 9 days (IQR 5–18 days), p 0.42).
Subgroup analyses
In a subgroup of patients with severe sepsis (n = 114), DET was
performed in 65 cases (57.0%). The strategy of de-escalation
was not associated with increased rates of adverse outcome
among severe sepsis patients (30-day mortality rates in DET
and N-DET subjects, 16.9% vs. 34.7%, respectively, p 0.03;TABLE 5. Clinical failure: multivariate analysis
Risk ratio 95% CI p
Model intercept 0.08 0.04–0.16 <0.01
De-escalation 0.89 0.63–1.27 0.54
Pneumonia Severity Index class IV–V 1.01 1.00–1.02 0.05
Macrolide therapy 0.97 0.66–1.43 0.89
Need for intensive care 4.08 2.39–6.97 <0.01
Severe sepsis 1.70 0.98–2.96 0.06
Statistically signiﬁcant p-values are in bold.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeclinical failure rates in DET and N-DET subjects, 40.0% vs.
52.4%, p 0.22). Among 198 patients with monomicrobial CAP
due to S. pneumoniae, DET was not associated with higher rates
of 30-day mortality and clinical failure (30-day mortality rates in
DET and N-DET subjects, 9.7% vs. 23.6% respectively, p < 0.01;
clinical failure rates in DET and N-DET subjects, 17.3% vs.
41.2%, p < 0.01).DiscussionThis study has demonstrated that DET is performed in almost
two-thirds of the bacteraemic patients hospitalized with CAP,
and that one of the main drivers for this is the patient’s response
during hospitalization. DET is not associated with an increased
risk of either 30-day mortality or clinical failure during hospi-
talization. Furthermore, DET does not seem to lead to higher 30-
day mortality and clinical failure rates when used in difﬁcult
clinical settings, such as in patients with severe sepsis.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 936.e11–936.e18
936.e17 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIIn 2014, several studies evaluated the safety and the efﬁcacy
of DET [6–8,11,30]. Unfortunately, the results of these studies
were divergent. In the observational study by Garnacho-
Montero et al., DET was associated with reduced risks of in-
hospital mortality and 90-day mortality [7]. Mokart et al. eval-
uated the performance of DET in neutropenic patients with
severe sepsis. DET did not modify the risk of death within the
ﬁrst 30 days or within 1 year after ICU discharge [8]. Although
it was a secondary endpoint in the study by Koupetori et al.,
DET was not associated with an increased risk of adverse
outcomes among patients with Gram-negative bloodstream
infection [30]. Cremers et al. found that de-escalating broad-
spectrum antibiotic treatment to penicillin monotherapy was
not associated with an increased risk of mortality in patients
with pneumococcal bacteraemia. Moreover, they found that
DET in pneumococcal pneumonia cases was associated with a
decreased risk of mortality [11]. Leone et al. performed the ﬁrst
randomized trial on DET in severe sepsis. The authors showed
that DET was inferior to continuation of the initial empirical
antibiotic therapy in terms of length of ICU stay. This trial had
some limitations: (a) the discontinuation of companion antibi-
otics (aminoglycoside, ﬂuoroquinolone, or macrolide) was
permitted by the study protocol in both the de-escalation
group and the continuation group—as a consequence, some
patients whose therapy was de-escalated were included in the
continuation group; (b) the primary endpoint was time from
study inclusion and ICU discharge—this is a surrogate
endpoint, and it may have been severely affected by the number
of patients who died during the ICU stay; and (c) the sample
size of the study was small (n = 116) [6]. Owing to the above
bias and limitations, the results of this trial should be analysed
with caution.
Although not conclusive, the evidence provided by our study
supports the use of DET for bacteraemic patients with CAP, in
line with the results of other observational studies [7,8].
Moreover, our ﬁndings support the safety of DET in the setting
of lung infections: by focusing on bacteraemic patients with
CAP, we avoided heterogeneity biases. Kollef and Joung ach-
ieved similar results [31]. Finally, our study showed more
extensive use of de-escalation than the rates (39–52%) re-
ported in previous studies [9,10,32]. It is of note that this study
showed a prolonged duration of the antibiotic treatment among
bacteraemic patients with CAP (median duration: 12 days), and
an even longer duration among those patients whose therapy
was de-escalated. The optimal duration of antibiotic therapy
among bacteraemic patients with CAP is still a matter of con-
troversy, and no speciﬁc recommendations are currently
available. As a result, clinicians probably overtreated patients.
Why DET patients were treated for a signiﬁcantly longer period
than N-DET patients is difﬁcult to explain. The results of theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectrecently completed ‘Duration Trial’ (clinical trial:
NCT01492387) will provide evidence to identify the optimal
duration of therapy for bacteraemic patients with CAP.
This study has several noteworthy limitations. As this is a
retrospective observational cohort study, we cannot make any
deﬁnitive inference about the association between DET use and
patient outcomes. Our study lacked detailed information about
the adverse events associated with antibiotic therapy and about
the follow-up period. Follow-up data would have been
extremely important to estimate the recurrence of CAP, the
rate of re-hospitalization, the causes of late mortality, and the
development of drug resistance. The relatively small number of
patients with severe sepsis limited our ability to detect signiﬁ-
cant differences between DET and N-DET patients in this
clinical subset. Finally, we did not address other important
questions regarding bacteraemic CAP, such as the effect on
outcome of switching from intravenous to oral therapy.
In conclusion, our ﬁndings suggest that DET is not associated
with adverse outcomes in the setting of bacteraemic patients
presenting with CAP. Although non-deﬁnitive, the evidence
generated by this study supports the design of prospective
studies and randomized clinical trials to further evaluate the use
of DET among bacteraemic patients with CAP.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsThe preliminary results of this study were presented at the 54th
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